HER2 Testing and the Utility of Ki67

Video

Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, comments on HER2 testing and the utility of Ki67.

Clinical Pearls

  • Recent ASCO-CAP guidelines lay out what is considered to be HER2 positive, negative, or equivocal.
  • HER2 testing should be done in high volume, well-equipped, quality-assured pathology centers.
  • The role for Ki67 as a prognostic marker is well-studied, though significant issues remain regarding its predictive utility and validity.
  • These issues must be addressed before Ki67 is used routinely in clinical practice.

Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, comments on HER2 testing and the utility of Ki67.

Related Videos
Video 7 - "Unmet Needs and Future Directions in HER2+ Breast Cancer"
Video 6 - "Current Approaches to Treatment Sequencing in HER2+ Breast Cancer"
Video 5 - "Exciting Developments in HER2+ Breast Cancer"
Video 4 - "KATHERINE: Adjuvant T-DM1 vs Trastuzumab for Residual Invasive HER2+ Breast Cancer"
Video 3 - "APHINITY Trial: Pertuzumab for Patients with HER2+ Breast Cancer"
Related Content